TRAW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Traws Pharma Inc (TRAW) is not a good buy for a beginner investor seeking long-term growth at this time. The stock is facing significant negative catalysts, including delays in its key drug program and downgrades from analysts. The technical indicators are bearish, and there are no strong proprietary trading signals to suggest an immediate opportunity. Given the lack of positive momentum, it is better to hold off on investing in this stock for now.
The technical indicators for TRAW are bearish. The MACD histogram is negative (-0.0649) and contracting, suggesting weak momentum. RSI is neutral at 25.395, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 0.756), with resistance levels far above (R1: 1.383).
NULL identified. No recent positive news or events to drive the stock upward.
The company's Phase 2a human influenza challenge study for its flu drug tivoxavir marboxil has been deferred due to a negative review by the UK's MHRA. This has significantly impacted market sentiment and caused a 28% drop in after-hours trading. Analysts have downgraded the stock to Neutral, citing a lack of visibility on future growth drivers and concerns about the company's balance sheet.
No financial data available for analysis. The latest quarter's performance could not be assessed due to missing data.
Analyst sentiment is negative. H.C. Wainwright downgraded the stock to Neutral from Buy, reducing the price target from $8 to $1. Ladenburg also downgraded the stock to Neutral, citing setbacks in the company's flu program and concerns about its financial stability.
